

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1 style="text-align: center;">TRANSMITTAL FORM</h1> <p style="text-align: center;">(to be used for all correspondence after initial filing)</p>		Application Number	10/509127-Conf. #4051
		Filing Date	September 28, 2004
		First Named Inventor	Piotr GRACZYK
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	5	Attorney Docket Number	0102286.00152US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard 20 References
<div style="border: 1px solid black; padding: 5px; min-height: 80px;"> Remarks </div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP		
Signature	<i>Hollie L. Baker</i>		
Printed name	Hollie L. Baker		
Date	<i>October 4, 2005</i>	Reg. No.	31,321

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: <i>Oct. 4, 2005</i>	Signature: <i>Robbin Graffius</i> (Robbin Graffius)

Rec'd PTO 06 OCT 2005


PATENT #6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRACZYK, et al.
Appln. No.: 10/509,127 Examiner: TBA
Filed: September 28, 2004 Group Art Unit: TBA
For: AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES
Atty. Docket No.: 102286.152 US1

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on October 4, 2005.


Robbin Graffius

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants bring to the attention of the Examiner the documents listed on the attached Form PTO/SB/08.

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No certification or fee is believed to be due. If, however, a fee is due, please charge our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO/SB/08 with the next communication.

GRACZYK, et al.
Appln. No: 10/509,127

Rec'd PCT/PTO 06 OCT 2005

Page 2

Dated: October 4,, 2005

Respectfully submitted,

Hollie L. Baker

Hollie L. Baker

Registration No. 31,321

Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000 (telephone)
(617) 526-5000 (facsimile)

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/509127-Conf. #4051
				Filing Date	September 28, 2004
				First Named Inventor	Piotr GRACZYK
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	0102286.00152US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-0035909-A1	06-22-2000	F. Hoffman - La Roche AG		√
	BB	WO-0035921-A1	06-22-2000	F. Hoffman - La Roche AG		√
	BC	WO-0056710-A1	09-28-2000	Glaxo Group Limited		√
	BD	WO-0112609-A1	02-22-2001	Signal Pharmaceuticals		√
	BE	WO-0147922-A2	07-05-2001	Aventis Pharma Ltd.		√
	BF	WO-0149288-A1	07-12-2001	Canada, et al.		√
	BG	WO-02081475-A1	10-17-2002	Eisai Co. Ltd.		√
	BH	WO-0216359-A1	02-28-2002	Glaxo Group Limited		√
	BI	WO-03082869-A1	10-09-2003	Eisai London		
	BJ	EP-0737685-A1	10-16-1996	Adir et Compagnie		
	BK	EP-1106621-A2	06-13-2001	Fuji Photo Film Co., Ltd.		√
	BL	WO-9921859-A1	05-06-1999	Glaxo Group Limited		√

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Cao, J. et al., "Distinct Requirements for p38 α and c-Jun N-terminal Kinase Stress-activated Protein Kinases in Difference Forms of Apoptotic Neuronal Death." <i>The Journal of Biological Chemistry</i> . 2004. Vol. 279, No. 34, 359033-13.	
	CB	Eilers, A. et al., "Direct inhibition of c-Jun N-terminal kinase in sympathetic neurons prevents c-jun promoter activation and NGF withdrawal-induced death" <i>Journal of Neurochemistry</i> . 1998. 76, 1439-54.	
	CC	Eilers, A. et al., "Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons" <i>The Journal of Neuroscience</i> . 1998. 8(5), 1713-24.	
	CD	Estus, S. et al., "Aggregated Amyloid- β Protein Induces Cortical Neuronal Apoptosis and Concomitant "Apoptotic" Pattern of Gene Induction." <i>The Journal of Neuroscience</i> . 1997. 17(20), 7736-45.	
	CE	Ham, J. et al., "A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death" <i>Neuron</i> . 1995. Vol. 14, 927-39.	
	CF	Lisnock, J. et al., "Activation of JNK3 α Requires both MKK4 and MKK7: Kinetic Characterization of in Vitro Phosphorylated JNK3 α 1" <i>Biochemistry</i> . 2000. Vol. 39, 3141-48.	
	CG	Watson, A. et al., "Phosphorylation of c-Jun Is Necessary for Apoptosis Induced by Survival	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/509127-Conf. #4051
				Filing Date	September 28, 2004
				First Named Inventor	Piotr GRACZYK
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	0102286.00152US1
Sheet	2	of	2		

		Signal Withdrawal in Cerebellar Granule Neurons" <i>The Journal of Neuroscience</i> . 1998. 18(2), 751-62.	
	CH	Young, P. R. et al., "Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site" <i>The Journal of Biological Chemistry</i> , 1997. Vol. 272, No. 18, 12116-21.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--